论文部分内容阅读
目的比较不同胰岛素给药方法对高血糖治疗的差异。方法64例需胰岛素治疗的高血糖病人住院进行了二种胰岛素强化治疗：①胰岛素泵连续皮下输往治疗（CSII组：30例，含1型DM8例，2型DM22例）；②多次皮下注射胰岛素治疗（MSII组：34例，含1型DM7例，2型DM27例）。二组治疗靶血糖值均为三餐前及睡前末梢血糖≥3．6mmol／L且≤7.2mmol／L，并至少二天。结果二种治疗血糖中位数有显著性差异（CSII：7．1，MSII：7．9，P＜0．001），平均高血糖控制无数（CSII：14.5±4．7天，MSII：22.5±7.5天，P＜0.01）、胰岛素用量（CSII：0.79±0.22U·kg(-1)／d，MSII0．63±0．20U·k(-1)／d，P＜0．01）均有显著性差异，而CSII组低血糖发生率却低于MSII组（0．9±1．2次／人vs1．9±2．5次／人，P＜0．05）。结论CSII治疗更符合生理状态下胰岛素分泌，可较MSII更快更有效地控制高血糖，并减少低血糖发生。
Objective To compare the differences in the treatment of hyperglycemia between different insulin administration methods. Methods Sixty-four patients with hyperglycemia requiring insulin therapy were enrolled in the hospital. Two kinds of intensive insulin therapy were performed: ① continuous subcutaneous infusion of insulin pump (CSII group: 30 cases, type 1 DM8, type 2 DM22); ② multiple subcutaneous Injecting insulin therapy (MSII group: 34 cases, including type 1 DM7 cases, type 2 DM27 cases). Blood sugar target value of the two groups were before meals and before meals and peripheral blood glucose ≥ 3.6mmol / L and ≤ 7.2mmol / L, and at least two days. Results There was a significant difference between the two treatments in median blood glucose (CSII: 7.1, MSII: 7.9, P <0.001) and mean high glycemic control (CSII: 14.5 ± 4.7 days, MSII: 22.5 ± 7.5 days, P <0.01), insulin dosage (CSII: 0.79 ± 0.22U · kg -1 / d, MSII 0.63 ± 0.20U · k -1 / d, P <0.01) The incidence of hypoglycaemia in CSII group was lower than that in MSII group (0.9 ± 1.2 times / person vs 1.9 ± 2.5 times / person, P <0.05). Conclusion CSII treatment is more consistent with insulin secretion in physiological state, which can control hyperglycemia faster and more effectively than MSII and reduce hypoglycemia.